Brief

On April 10, 2025, the French National Agency for the Safety of Medicines and Health Products (ANSM) issued an update regarding ANSM is launching an awareness campaign for the proper use of drugs in the treatment of anxiety and insomnia. The campaign aims to sensitize the public and healthcare professionals about the risks associated with benzodiazepines and related medications, which are highly prescribed and used for extended periods in France.

This content is restricted.

Highlights content goes here...

This content is restricted.

French National Agency for the Safety of Medicines and Health Products (ANSM)

Quick Insight
RADA.AI
RADA.AI
Hello! I'm RADA.AI - Regulatory Analysis and Decision Assistance. Your Intelligent guide for compliance and decision-making. How can i assist you today?
Suggested

Form successfully submitted. One of our GRI rep will contact you shortly

Thanking You!

Enter your Email

Enter your registered username/email id.

Enter your Email

Enter your email id below to signup.
Individual Plan
$125 / month OR $1250 / year
Features
Best for: Researchers, Legal professionals, Academics
Enterprise Plan
Contact for Pricing
Features
Best for: Law Firms, Corporations, Government Bodies